AAM
NKTR icon

Advisors Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Advisors Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-95
Closed -$31K – 1537
2019
Q4 		$31K Sell
95
-93
-49% -$27K ﹤0.01% 1437
2019
Q3 		$51K Sell
188
-66
-26% -$24.2K ﹤0.01% 1398
2019
Q2 		$136K Sell
254
-5
-2% -$2.51K ﹤0.01% 1255
2019
Q1 		$131K Sell
259
-8
-3% -$4.74K ﹤0.01% 1452
2018
Q4 		$132K Sell
267
-378
-59% -$228K ﹤0.01% 1297
2018
Q3 		$589K Buy
645
+136
+27% +$116K 0.01% 1003
2018
Q2 		$373K Buy
+509
New +$587K 0.01% 1121

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Advisors Asset Management's NKTR Position: Q1 2020 in Review

Advisors Asset Management sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 95 shares — an estimated $31K sold.

Advisors Asset Management first reported a position in NKTR in Q2 2018 and held it in 7 quarters. The position peaked at $589K in Q3 2018. 245 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

  • Advisors Asset Management reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Advisors Asset Management sold 95 Nektar Therapeutics shares in Q1 2020, an estimated $31K.
  • Advisors Asset Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 7 quarters.
  • Advisors Asset Management's Nektar Therapeutics position peaked at $589K in Q3 2018.
  • 245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Advisors Asset Management's 13F filing for Q1 2020, filed 15 May 2020.